质子医疗

Search documents
中广核核技术发展股份有限公司 第十届董事会第二十八次会议决议公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-06-09 22:55
Group 1 - The company held its 28th meeting of the 10th Board of Directors on June 6, 2025, with all 9 directors present [2][3] - The board approved the strategic project for proton medical treatment [4] - The board also approved a capital increase of 500 million RMB from the controlling shareholder to its wholly-owned subsidiary, CGN Medical Technology (Mianyang) Co., Ltd [5][21] Group 2 - The capital increase will allow the subsidiary to develop proton medical technology and will maintain the subsidiary's status as a controlled entity of the company [21][34] - The board's decision on the capital increase was made with the avoidance of related directors, ensuring compliance with regulations [22][61] - The company plans to hold its 2024 annual shareholders' meeting on June 30, 2025 [41][42] Group 3 - The company approved revisions to its articles of association and management regulations during the board meeting [10][13] - The independent directors unanimously agreed that the transaction pricing was fair and would not affect the company's independence [36][61] - The company has had previous related transactions amounting to 37.88 million RMB with its controlling shareholder in 2025 [37]
中广核技:控股股东向全资子公司增资5亿元
news flash· 2025-06-09 10:51
Core Viewpoint - The company Zhongguang Nuclear Technology (000881) announced that its controlling shareholder, Nuclear Technology Company, plans to increase capital by 500 million yuan to its wholly-owned subsidiary, Medical Technology Company, which will enhance its stake in the subsidiary to 44.13% [1] Group 1 - The capital increase will be used for research and development projects related to proton therapy and future operational development of Medical Technology Company [1] - After the capital increase, Zhongguang Nuclear Technology will hold 55.87% of Medical Technology Company, maintaining it as a controlling subsidiary [1] - The capital increase constitutes a related party transaction as Nuclear Technology Company is a wholly-owned subsidiary of China General Nuclear Power Group (003816), the actual controller of Zhongguang Nuclear Technology [1]